SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc. (Amendment)
$ENTA
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2023 | $14.00 | Neutral → Underweight | JP Morgan |
| 8/8/2023 | $49.00 → $18.00 | Buy → Hold | Jefferies |
| 12/9/2022 | $56.00 | Buy | H.C. Wainwright |
| 7/6/2022 | $62.00 | In-line → Outperform | Evercore ISI |
| 6/1/2022 | $39.00 | Underperform → In-line | Evercore ISI |
| 2/9/2022 | $80.00 → $68.00 | Market Perform | SVB Leerink |
| 1/13/2022 | $85.00 → $80.00 | Market Perform | SVB Leerink |
| 11/24/2021 | $55.00 → $73.00 | Perform | Oppenheimer |
HC Wainwright & Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:ENTA) with a Buy and lowers the price target from $28 to $27.
JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:ENTA) with a Market Outperform and lowers the price target from $23 to $22.
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.33) by 10.53 percent. This is a 17.88 percent increase over losses of $(1.79) per share from the same period last year. The company reported quarterly sales of $17.054 million which beat the analyst consensus estimate of $16.522 million by 3.22 percent. This is a 4.16 percent decrease over sales of $17.795 million the same period last year.
Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo Favorable Safety and Tolerability Observed Conference Call and Webcast to Discuss Data at 8:30 a.m. ET Today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data demonstrated that EDP-323 was generally safe and
Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal third quarter ended June 30, 2024. "We are
Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024 Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate Targeted for Q4 2024 Operations Supported by Cash and Marketable Securities Totaling $300.3 Million at March 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. "At Enanta, we are commit
Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo Favorable Safety and Tolerability Observed Conference Call and Webcast to Discuss Data at 8:30 a.m. ET Today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data demonstrated that EDP-323 was generally safe and
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will participate in three investor conferences being webcast in September: Baird 2024 Global Healthcare Conference: Fireside Chat at 2:35 p.m. ET on September 10, 2024 H.C. Wainwright 26th Annual Global Investment Conference: Fireside Chat at 10:00 a.m. ET on September 11, 2024 2024 Cantor Global Healthcare Conference: Fireside Chat at 10:55 a.m. ET on September 17, 2024 A live webcast of each event will be accessible by visiting the "Events and Presentations" section on t
Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal third quarter ended June 30, 2024. "We are
JP Morgan downgraded Enanta Pharmaceuticals from Neutral to Underweight and set a new price target of $14.00
Jefferies downgraded Enanta Pharmaceuticals from Buy to Hold and set a new price target of $18.00 from $49.00 previously
H.C. Wainwright initiated coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $56.00
SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)
SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)
SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)
4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
S-8 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys